British biopharma firm looking to develop further in Zhangjiang
AstraZeneca, the second largest biopharmaceutical multinational in China, hopes to strengthen its R&D and develop further in Shanghai's Zhangjiang High Tech Park, said Feng Ji, general manager at AstraZeneca China, on Oct 10.
The remarks were made during a meeting between Feng and Weng Zuliang, Party secretary of Shanghai's Pudong New Area, to discuss the company's business development in China.
Weng Zuliang mentioned Pudong's good growth momentum last year and said that the development of enterprises and the region is interdependent.
Weng introduced a series of measures Pudong has taken to better serve domestic and foreign enterprises.
The Overseas Talent Bureau, the first of its kind in China, was launched in Pudong on June 16 to deal with issues such as permanent residence and work permits for foreigners.
Simplified trade procedures were carried out to help companies save time and lower cost.
The Party secretary vowed that Pudong, home to the China (Shanghai) Pilot Free Trade Zone, will do its best to serve various enterprises. He also hoped that enterprises will make full use of the FTZ's preferential policies to develop better.
Zhangjiang High Tech Park, located in Pudong, has been incorporated into the China (Shanghai) Pilot Free Trade Zone since April 2015.
AstraZeneca, headquartered in London, is a global science-led biopharmaceutical company that specializes in the R&D, production and sales of prescription drugs. Its Chinese headquarters and research center opened in Zhangjiang in 2012 and 2013 respectively. Its staff members in China exceed 10,000 at present.
AstraZeneca, a UK-based biopharmaceutical company, set up its Chinese headquarters and research center in Shanghai's Zhangjiang High Tech Park in 2012 and 2013 respectively. [Photo provided to chinadaily.com.cn]